TREKKA Therapeutics

Executive Summary

TREKKA Therapeutics is a Cambridge-based biotechnology company founded in 2021, focused on solving critical drug delivery challenges through its proprietary CAPRO™ platform. CAPRO is a novel biomaterial excipient designed to enhance the solubility, stability, and bioavailability of both biologics and small molecule drugs. By addressing common formulation hurdles, TREKKA positions itself as a strategic partner for pharmaceutical and biotech companies seeking to accelerate drug development and improve therapeutic outcomes. The platform's versatility could enable broader applicability across multiple therapeutic areas, potentially reducing development timelines and costs for partners. As a private, early-stage company, TREKKA is advancing its platform through internal R&D and collaborative engagements. Key near-term milestones include securing initial partnerships to validate platform utility, generating preclinical proof-of-concept data, and closing a Series A financing round to scale operations. While still pre-revenue, TREKKA's innovative approach to drug delivery addresses a persistent need in the industry, offering a potential solution for compounds with poor pharmacokinetics. Success will depend on its ability to demonstrate tangible benefits in partner programs and attract funding to support further development.

Upcoming Catalysts (preview)

• Q4 2026Announcement of first strategic partnership with a pharmaceutical or biotech company50% success
• Q2 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal60% success
• Q3 2026Completion of Series A financing round55% success